Skip to main content

News Archive

News Archive - School of Medicine

Cancer Survivor and Noted Physician-Scientist Sandra Horning to Receive Roth Award

February 14, 2017

Sandra Horning, MD, Chief Medical Officer and executive vice president of global development for Roche and Genentech, a member of the Roche Group, has been named the 2017 recipient of the Duane Roth Memorial Award, which will be presented February 16 at the annual Industry/Academia Translational Oncology Symposium at UC San Diego Moores Cancer Center.

Innovators Wanted: UC Health Hack Seeks New Ideas to Solve Critical Health Problems

February 9, 2017

Think you have an idea that will change health care but need the means to bring your innovation to fruition? Register for UC Health Hack, a two-day interdisciplinary hackathon that will bring students, physicians, researchers, industry professionals and community members together to grapple with integrative medicine and global health issues in a fast-paced competition.

Gene Variant Identified for Kawasaki Disease Susceptibility

February 9, 2017

Researchers at University of California San Diego School of Medicine, with colleagues at Rady Children’s Institute for Genomic Medicine and in London and Singapore, have conducted novel whole genome sequencing of a family in which two of four children were affected by Kawasaki disease. They have identified plausible gene variants that predispose some children to developing the disease.

UC San Diego Health Named Official Health Care Provider of the San Diego Padres

February 7, 2017

UC San Diego Health and the San Diego Padres reached an agreement on a multi-year partnership to become the Major League Baseball team’s Official Health Care Provider.

Study: Medicare Could Overpay Medicare Advantage Plans by $200 Billion Over Ten Years

February 6, 2017

Research conducted at University of California San Diego School of Medicine found that current trends in diagnostic coding for patient risk scores will lead to Medicare overpaying Medicare Advantage (MA) plans substantially through 2026-likely to the tune of hundreds of billions of dollars. The study is published in the February issue of Health Affairs.

Severe Newborn Jaundice Could be Preventable, Mouse Study Shows

February 6, 2017

In a mouse study, researchers at University of California San Diego School of Medicine have identified a protein that inhibits the enzyme that breaks down bilirubin in newborns. Methods that block this inhibitor, and thus restore the enzyme’s activity, could provide a new therapeutic approach for preventing or treating severe newborn jaundice. The study is published February 6, 2017 by the Proceedings of the National Academy of Sciences.

Campuswide Innovation at UC San Diego Gets $2.2 Million Boost from Elected Officials, UC System

February 6, 2017

Thanks to local and regional elected officials who helped assure passage of Assembly Bill 2664, the University of California San Diego has received $2.2 million from the UC system to help spur innovation and entrepreneurship on campus.

SDSC’s ‘Comet’ Supercomputer Surpasses ‘10,000 Users’ Milestone

February 2, 2017

Comet, the petascale supercomputer at the San Diego Supercomputer Center (SDSC), an Organized Research Unit of UC San Diego, has easily surpassed its target of serving at least 10,000 researchers across a diverse range of science disciplines, from astrophysics to redrawing the “tree of life”.

UC San Diego Researcher to Study Most Effective Treatment for Kawasaki Disease

February 2, 2017

Researchers at University of California San Diego School of Medicine, Rady Children’s Hospital-San Diego and Betty Irene Moore School of Nursing at University of California Davis have received a $2 million grant from the Patient-Centered Outcomes Research Institute (PCORI) for a three-year study to look at the effectiveness of two treatment options for children with KD who are resistant to initial therapy.

Potential New Drug Class Hits Multiple Cancer Cell Targets, Boosting Efficacy and Safety

February 1, 2017

In a new paper published this week in PNAS, researchers at the University of California San Diego School of Medicine and Moores Cancer Center, in collaboration with colleagues at Rady Children’s Hospital-San Diego, the University of Colorado School of Medicine and SignalRx, a San Diego-based biopharmaceutical company, describe a potential new class of anti-cancer drugs that inhibit two or more molecular targets at once, maximizing therapeutic efficiency and safety.
Category navigation with Social links